ATE271867T1 - Behandlung der harninkontinenz und zusammenstellung dafür - Google Patents

Behandlung der harninkontinenz und zusammenstellung dafür

Info

Publication number
ATE271867T1
ATE271867T1 AT97910115T AT97910115T ATE271867T1 AT E271867 T1 ATE271867 T1 AT E271867T1 AT 97910115 T AT97910115 T AT 97910115T AT 97910115 T AT97910115 T AT 97910115T AT E271867 T1 ATE271867 T1 AT E271867T1
Authority
AT
Austria
Prior art keywords
urinary incontinence
treatment
composition
serotonin
histamine
Prior art date
Application number
AT97910115T
Other languages
English (en)
Inventor
John Mcmichael
Original Assignee
Milkhaus Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milkhaus Lab Inc filed Critical Milkhaus Lab Inc
Application granted granted Critical
Publication of ATE271867T1 publication Critical patent/ATE271867T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97910115T 1996-10-17 1997-10-16 Behandlung der harninkontinenz und zusammenstellung dafür ATE271867T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/731,702 US5877198A (en) 1996-10-17 1996-10-17 Treatment of urinary incontinence
PCT/US1997/018601 WO1998016225A1 (en) 1996-10-17 1997-10-16 Treatment of urinary incontinence and compositions for use therein

Publications (1)

Publication Number Publication Date
ATE271867T1 true ATE271867T1 (de) 2004-08-15

Family

ID=24940633

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97910115T ATE271867T1 (de) 1996-10-17 1997-10-16 Behandlung der harninkontinenz und zusammenstellung dafür

Country Status (9)

Country Link
US (1) US5877198A (de)
EP (1) EP0946174B1 (de)
JP (1) JP2001502336A (de)
AT (1) ATE271867T1 (de)
AU (1) AU729675B2 (de)
CA (1) CA2269031C (de)
DE (1) DE69730045T2 (de)
IL (1) IL129267A (de)
WO (1) WO1998016225A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6156780A (en) * 1996-10-17 2000-12-05 Milkhaus Laboratory, Inc. Treatment of fecal incontinence
WO2014066672A1 (en) * 2012-10-26 2014-05-01 Beech Tree Labs, Inc. Method of treating muscular weakness comprising administering a composition comprising an effective amount of histamine and/or serotonin
EP3727436B1 (de) 2017-12-21 2023-11-15 Resolys Bio, Inc. Zusammensetzung zur behandlung des ehlers-danlos-syndroms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880626A (en) * 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
US4692332A (en) * 1985-01-18 1987-09-08 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms
US4689222A (en) * 1985-01-18 1987-08-25 Mcmichael John Methods and materials for alleviation of pain symptoms of malignant neoplasia
US4970071A (en) * 1985-01-18 1990-11-13 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms
US4966753A (en) * 1987-08-18 1990-10-30 Molecular Rx, Inc. Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms
WO1989002220A1 (en) * 1987-09-10 1989-03-23 John Mcmichael Method and composition for enhancing animal fertility
JP2980677B2 (ja) * 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
EP0760676B1 (de) * 1994-05-25 2001-07-11 McMICHAEL, John Mittel und methoden zur behandlung von plaque-krankheiten
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
EP0766570B1 (de) * 1995-04-13 2001-12-12 Milkhaus Laboratory, Inc. Methoden zur behandlung von atemwegserkrankungen
US5610174A (en) * 1995-06-02 1997-03-11 Synaptic Pharmaceutical Corporation Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence

Also Published As

Publication number Publication date
AU729675B2 (en) 2001-02-08
DE69730045D1 (de) 2004-09-02
IL129267A (en) 2003-10-31
JP2001502336A (ja) 2001-02-20
AU4757297A (en) 1998-05-11
CA2269031A1 (en) 1998-04-23
EP0946174A4 (de) 2002-10-23
EP0946174B1 (de) 2004-07-28
IL129267A0 (en) 2000-02-17
DE69730045T2 (de) 2005-07-21
CA2269031C (en) 2003-09-09
EP0946174A1 (de) 1999-10-06
WO1998016225A1 (en) 1998-04-23
US5877198A (en) 1999-03-02

Similar Documents

Publication Publication Date Title
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
EA200000994A1 (ru) Применение кабэрголина при лечении синдрома усталых ног
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
ATE232396T1 (de) Oxydiertes thymosin beta 4
DK0839143T3 (da) Tetralinforbindelser med MDR-aktivitet
BG105302A (en) Means for improving cognition
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
RS52011B (sr) Nova primena derivata taksoida
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
BR0115882A (pt) Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE293972T1 (de) Behandlung von chronischen schmerzen
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
MD1140B1 (en) Remedy possessing a regenerative and cytoprotective activity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties